• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » CSSi appoints Ronald Bukowski to New Medical and Clinical Advisory Board

CSSi appoints Ronald Bukowski to New Medical and Clinical Advisory Board

June 12, 2014
CenterWatch Staff

CSSi, a provider of patient recruitment solutions for the clinical research industry, recently announced the formation of the company's Medical and Clinical Advisory Board (MCAB) and the appointment of Ronald M. Bukowski, M.D., as its chairman.

The MCAB, with Bukowski's leadership, will help provide insight across a variety of therapeutic areas and set strategic goals for the advancement and development of CSSi's work within the clinical research industry to shorten the timelines of getting new drugs to market. Additionally, the MCAB will strive to identify best practices based on evidence and clinical guidelines to achieve optimum outcomes of research trials.

Bukowski is an emeritus staff at the Taussig Cancer Center and the Cleveland Clinic Foundation. He recently was professor of Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University and the deputy director of the Cleveland Clinic Taussig Cancer Center. He was the director of the Experimental Therapeutics Program at the Cleveland Clinic Cancer Center, and held the James Zito Chair in Cancer Research from 2001 to 2008. Bukowski is a fellow of the American College of Physicians and a member of numerous professional societies, including the American Society of Clinical Oncology and the American Association of Cancer Research.

He is a lifelong researcher with interests in new drug development and investigation, as well as biologic response modifiers and the biology of renal cell carcinoma. Currently, Bukowski is the chairman of the medical committee of the Kidney Cancer Association and chairman of its board of directors.

Additional physicians will be added in the near future, allowing for expansion of global regulatory specialties and therapeutic diversity which will reflect the international leadership position of CSSi in the patient recruitment industry.

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing